Mechanisms and clinical significance of histone deacetylase inhibitors: Epigenetic glioblastoma therapy

Anticancer Research

Volumn 35, Issue 2, 2015, Pages 615-625

  Lee, Philip ^a   Murphy, Ben ^a   Miller, Rickey ^a   Menon, Vivek ^a   Banik, Naren L ^a,b   Giglio, Pierre ^a,c   Lindhorst, Scott M ^a   Varma, Abhay K ^a   Vandergrift, William A ^a   Patel, Sunil J ^a   Das, Arabinda ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Clinical trials; Epigenetics; Glioblastoma; Histone deacetylase inhibitor; Preclinical trials; Review

Indexed keywords

BENZAMIDE DERIVATIVE; FATTY ACID; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; OLIGOPEPTIDE;

GENETIC EPIGENESIS; GLIOBLASTOMA; HUMAN;

BENZAMIDES; EPIGENESIS, GENETIC; FATTY ACIDS; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; OLIGOPEPTIDES;

EID: 84923650709     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Wilson TA, Karajannis MA and Harter DH: Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int 5: 64, 2014.
2. Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, Iavarone A, Aldape K, Brennan CW, Jabado N and Pfister SM: Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer 14(2):92-107, 2014.
3. Ahmad M, Hamid A, Hussain A, Majeed R, Qurishi Y, Bhat JA, Najar RA, Qazi AK, Zargar MA, Singh SK and Saxena AK: Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy. DNA Cell Biol 31 Suppl 1: S62-71, 2012.
4. Shabason JE, Tofilon PJand Camphausen K: Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med 15(12): 2735-44, 2011.
5. Bezecny P: Histone deacetylase inhibitors in glioblastoma: preclinical and clinical experience. Med Oncol 31(6): 985, 2014.
6. Bojang P Jr and Ramos KS: The promise and failures of epigenetic therapies for cancer treatment. Cancer treatment reviews 40( 1): 153-169, 2014.
7. Maleszewska M and Kaminska B: Is glioblastoma an epigenetic malignancy? Cancers 5(3): 1120-1139, 2013.
8. Parbin S, Kar S, Shilpi A, Sengupta D, Deb M, Rath SK and Patra SK: Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem 62(1): 11-33, 2014.
9. Kelly RD and Cowley SM: The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem Soc Trans 41(3): 741-749, 2013.
10. Cohen AL, Piccolo SR, Cheng L, Soldi R, Han B, Johnson WE and Bild AH: Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers. BMC Med Genomics 6: 35, 2013.
11. Lucio-Eterovic AK, Cortez MA, Valera ET, Motta FJ, Queiroz RG, Machado HR, Carlotti CG Jr, Neder L, Scrideli CA and Tone LG: Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 8: 243, 2008.
12. New M, Olzscha H and La Thangue NB: HDAC inhibitorbased therapies: can we interpret the code? Mol Oncol 6(6): 637-656, 2012.
13. Gantt SL, Gattis SG and Fierke CA: Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry 45(19): 6170-6178, 2006.
14. Bose P, Dai Y and Grant S: Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights. Pharmacol Ther 143(3): 323-336, 2014.
15. Dickinson M, Johnstone RW and Prince HM: Histone deacetylase inhibitors: potential targets responsible for their anticancer effect. Invest New Drugs 28 Suppl 1: S3-20, 2010.
16. Gray SG and Ekström TJ: The human histone deacetylase family. Exp Cell Res 262(2): 75-83, 2001.
17. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S and van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370(Pt 3): 737-749, 2003.
18. Kim HJ and Bae SC: Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 3(2): 166-179, 2011.
19. Marks PA and Xu WS: Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107(4): 600-8, 2009.
20. Schrump DS: Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 15(12): 3947-3957, 2009.
21. Mund C and Lyko F: Epigenetic cancer therapy: Proof of concept and remaining challenges. Bioessays 32(11): 949-957, 2010.
22. Khan O and La Thangue NB: HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90(1): 85-94, 2012.
23. Bolden JE, Peart MJ and Johnstone RW: Johnstone, Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9): 769-784, 2006.
24. Gryder BE, Sodji QH and Oyelere AK: Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 4(4): 1369-1370, 2012.
25. Leten C, Struys T, Dresselaers T and Himmelreich U: in vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models. J Neurooncol 119(2): 297-306, 2014.
26. Ghosh SK, Perrine SP, Williams RM and Faller DV: Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood 119(4): 1008-1017, 2012.
27. Blackwell L, Norris J, Suto CM and Janzen WP: The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life sciences 82(21): 1050-1058, 2008.
28. Eilertsen KJ, Power, RA and Rim JS: Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator, 2011, Google Patents.
29. Dokmanovic M, Clarke C and Marks PA: Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5( 10): 981-989, 2007.
30. Bezecny P: Histone deacetylase inhibitors in glioblastoma: preclinical and clinical experience. Med Oncol, 31(6): 985, 2014.
31. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J and Jaye M: Identification of novel isoform-selective inhibitors within class I histone deacetylases. Journal of Pharmacology and Experimental Therapeutics 307(2): 720-728, 2003.
32. Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA and Lock R: Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61(2): 245-252, 2014.
33. Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar KS, Rudraraju V, Mittapalli RK, Gaasch JA, Bohn KA, Thorsheim HR, Liewehr DJ, Davis S, Reilly JF, Walker R, Bronder JL, Feigenbaum L, Steinberg SM, Camphausen K, Meltzer PS, Richon VM, Smith QR and Steeg PS: Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 15(19): 6148-6157, 2009.
34. Hooker JM, Kim SW, Alexoff D, Xu Y, Shea C, Reid A, Volkow N and Fowler JS: Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of (C)MS-275 using Positron Emission Tomography. ACS Chem Neurosci 1(1): 65-73, 2010.
35. Egler V, Korur S, Failly M, Boulay JL, Imber R, Lino MM and Merlo A: Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clin Cancer Res 14(10): 3132-3140, 2008.
36. Stapleton SL, Thompson PA, Ou CN, Berg SL, McGuffey L, Gibson B and Blaney SM: Plasma and cerebrospinal fluid pharmaco kinetics of valproic acid after oral administration in non-human primates. Cancer Chemother Pharmacol 61(4): 647-652, 2008.
37. Wang Z, Leng Y, Tsai LK, Leeds P and Chuang DM: Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab 31(1): 52-57, 2011.
38. Garbes L, Riessland M, Hölker I, Heller R, Hauke J, Tränkle C, Coras R, Blümcke I and Hahnen E, Wirth B: LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum Mol Genet 18(19): 3645-3658, 2009.
39. Berg SL, Stone J, Xiao JJ, Chan KK, Nuchtern J, Dauser R, McGuffey L, Thompson P and Blaney SM: Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol 54(1): 85-88, 2004.
40. Grayson DR, Kundakovic M and Sharma RP: Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Molecular pharmacology 77(2): 126-135, 2010.
41. Entin-Meer M, Yang X, VandenBerg SR, Lamborn KR, Nudelman A, Rephaeli A and Haas-Kogan DA: in vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro Oncol 9(2): 82-88, 2007.
42. Enna SJ, August JT and Murad F: GABA. Vol. 54. 2006: Academic Press.
43. Marks PA, Richon VM and Rifkind RA: Treatment of neurodegenerative diseases and cancer of the brain 2004, Google Patents.
44. Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, Kulp S, La Perle KM, Chen CS, Chang LS and Welling DB: Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope 122(1): 174-189, 2012.
45. Butler R and Bates GP: Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7(10): 784-796, 2006.
46. Available from: https://clinicaltrials.gov/ct2/home.
47. Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I and Phillips DR: Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res 61(22): 8194-8202, 2001.
48. Lawless MW, Norris S, O'Byrne KJ and Gray SG: Targeting histone deacetylases for the treatment of disease. J Cell Mol Med 13(5): 826-852, 2009.
49. Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F and Bhatnagar A: Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45(3): 381-386, 2004.
50. Gensert JM, Baranova OV, Weinstein DE and Ratan RR: CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibi tion in glioma cells. Neurobiology of disease 26(3): 671-680, 2007.
51. Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T, Tamura Y, Satone A, Ide W, Hashimoto I and Kamada H: Histone deacetylase inhibitors such as sodium buty rate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain tumor pathology 18(2): 109-114, 2001.
52. Sawa H, Murakami H, Ohshima Y, Murakami M, Yamazaki I, Tamura Y, Mima T, Satone A, Ide W, Hashimoto I and Kamada H: Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain tumor pathology 19(2): 77-81, 2002.
53. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA and Nelson WG, Simons JW: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 2(2): 379-387, 1996.
54. Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD and Carducci MA: Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol 7(2): 177-182, 2005.
55. Ammerpohl O, Trauzold A, Schniewind B, Griep U, Pilarsky C, Grutzmann R, Saeger HD, Janssen O, Sipos B, Kloppel G and Kalthoff H: Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. British journal of cancer 96(1): 73-81, 2006.
56. Asklund T, Kvarnbrink S, Holmlund C, Wibom C, Bergenheim T, Henriksson R and Hedman H: Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. Anticancer Res 32(7): 2407-2413, 2012.
57. Lopez CA, Feng FY, Herman JM, Nyati MK, Lawrence TS and Ljungman M: Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. International Journal of Radiation Oncology∗ Biology∗ Physics 69(1): 214-220, 2007.
58. Entin-Meer M, Rephaeli A, Yang X, Nudelman A, Nudelman A and Haas-Kogan DA: AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Cancer Lett 253(2): 205-214, 2007.
59. Barker CA, Bishop AJ, Chang M, Beal K and Chan TA: Valproic acid use during radiation therapy for glioblastoma associated with improved survival. International Journal of Radiation Oncology∗ Biology∗ Physics 86(3): 504-509, 2013.
60. Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V and Wolff JE: Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 28(4C): 2437-2442, 2008.
61. Eyüpoglu IY, Hahnen E, Tränkle C, Savaskan NE, Siebzehnrübl FA, Buslei R, Lemke D, Wick W, Fahlbusch R and Blümcke I: Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Molecular cancer therapeutics 5(5): 1248-1255, 2006.
62. Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD and Fine HA: A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol 13(5): 509-516, 2011.
63. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, Farra Y, Young D and Grever M: Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12(13): 3997-4003, 2006.
64. Burgess AJ, Pavey S, Warrener R, Hunter LJ, Piva TJ, Musgrove EA, Saunders N, Parsons PG and Gabrielli BG: Up-regulation of p21WAF1/CIP1 by histone deacetylase inhibitors reduces their cytotoxicity. Molecular pharmacology, 60(4): 828-837, 2001.
65. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM and La Quaglia MP: The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergisti cally with alltrans retinoic acid. Cancer Res 61(9): 3591-3594, 2001.
66. Romanski A, Schwarz K, Keller M, Wietbrauk S, Vogel A, Roos J, Oancea C, Brill B, Krämer OH, Serve H, Ruthardt M and Bug G: Deacetylase inhibitors modulate proliferation and selfrenewal properties of leukemic stem and progenitor cells. Cell Cycle 11(17): 3219-26, 2012.
67. Bai LY, Omar HA, Chiu CF, Chi ZP, Hu JL and Weng JR: Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. Cancer Chemother Pharmacol 68(2): 489-496, 2011.
68. Yang YL, Huang PH, Chiu HC, Kulp SK, Chen CS, Kuo CJ, Chen HD and Chen CS: Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Aktdependent mechanism. Biochem Biophys Res Commun 435(1): 107-112, 2013.
69. Kim EH, Kim HS, Kim SU, Noh EJ, Lee JS and Choi KS: Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subse quent down-regulation of survivin and XIAP. Oncogene 24(46): 6877-6889, 2005.
70. Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ and Wen PY: Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 107( 1): 133-138, 2012.
71. Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, Fourneau N, Hellemans P, Elsayed Y, McClue S, Smit JW, Forslund A, Phelps C, Camm J, Evans TR, de Bono JS and Banerji U: A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clinical Cancer Research 19(15): 4262-4272, 2013.
72. Sharma NL, Groselj B, Hamdy FC and Kiltie AE: The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. BJU Int 111( 4): 537-542, 2013.
73. Bajbouj K, Mawrin C, Hartig R, Schulze-Luehrmann J, Wilisch-Neumann A, Roessner A and Schneider-Stock R: P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. J Neurooncol 107(3): 503-516, 2012.
74. Gammoh N, Lam D, Puente C, Ganley I, Marks PA and Jiang X: Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proceedings of the National Academy of Sciences 109(17): 6561-6565, 2012.
75. Premkumar DR, Jane EP, Agostino NR, DiDomenico JD and Pollack IF: Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa up-regulation, Mcl-1 cleavage, and DNA damage. Molecular carcinogenesis 52(2): 118-133, 2013.
76. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon E, Jaeckle K and Galanis E: Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 14(2): 215-221, 2012.
77. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J and Buckner JC: Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. Clin Oncol 27(19): 3262-3263, 2009.
78. Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, Urrutia RA and Sarkaria JN: Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT up-regulation in glioblastoma xenografts. Clinical Cancer Research 18(15): 4070-4079, 2012.
79. Wallace GC 4th, Haar CP, Vandergrift WA 3rd, Giglio P, Dixon-Mah YN, Varma AK, Ray SK, Patel SJ, Banik NL and Das A: Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition. J Neurooncol 114(1): 43-50, 2013.